Literature DB >> 20801187

Analysis of the effects of androgens and training on myostatin propeptide and follistatin concentrations in blood and skeletal muscle using highly sensitive immuno PCR.

Patrick Diel1, Thorsten Schiffer, Stephan Geisler, Torsten Hertrampf, Stephanie Mosler, Sven Schulz, Karl Florian Wintgens, Michael Adler.   

Abstract

Myostatin propeptide (MYOPRO) and follistatin (FOLLI) are potent myostatin inhibitors. In this study we analysed effects of training and androgens on MYOPRO and FOLLI concentrations in blood and skeletal muscle using Immuno PCR. Young healthy males performed either a 3-month endurance training or a strength training. Blood and biopsy samples were analysed. Training did not significantly affect MYOPRO and FOLLI concentrations in serum and muscle. To investigate whether total skeletal muscle mass may affect circulating MYOPRO and FOLLI levels, blood samples of tetraplegic patients, untrained volunteers and bodybuilders were analysed. MYOPRO was significantly increased exclusively in the bodybuilder group. In orchiectomised rats MYOPRO increased in blood and muscle after treatment with testosterone. In summary our data demonstrate that moderate training does not affect the concentrations of MYOPRO to FOLLI. In contrast androgen treatment results in a significant increase of MYOPRO in skeletal muscle and serum.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801187     DOI: 10.1016/j.mce.2010.08.015

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

Review 1.  Emerging technologies to increase ligand binding assay sensitivity.

Authors:  Saloumeh K Fischer; Alison Joyce; Mark Spengler; Tong-Yuan Yang; Yao Zhuang; Marianne Scheel Fjording; Alvydas Mikulskis
Journal:  AAPS J       Date:  2014-10-18       Impact factor: 4.009

2.  RNA sequencing identifies upregulated kyphoscoliosis peptidase and phosphatidic acid signaling pathways in muscle hypertrophy generated by transgenic expression of myostatin propeptide.

Authors:  Yuanxin Miao; Jinzeng Yang; Zhong Xu; Lu Jing; Shuhong Zhao; Xinyun Li
Journal:  Int J Mol Sci       Date:  2015-04-09       Impact factor: 5.923

3.  Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay.

Authors:  H Robert Bergen; Joshua N Farr; Patrick M Vanderboom; Elizabeth J Atkinson; Thomas A White; Ravinder J Singh; Sundeep Khosla; Nathan K LeBrasseur
Journal:  Skelet Muscle       Date:  2015-07-15       Impact factor: 4.912

4.  Combinatory effects of siRNA-induced myostatin inhibition and exercise on skeletal muscle homeostasis and body composition.

Authors:  Stephanie Mosler; Karima Relizani; Etienne Mouisel; Helge Amthor; Patrick Diel
Journal:  Physiol Rep       Date:  2014-03-20

5.  Serum reference value of two potential doping candidates-myostatin and insulin-like growth factor-I in the healthy young male.

Authors:  Der-Sheng Han; Chi-Huang Huang; Ssu-Yuan Chen; Wei-Shiung Yang
Journal:  J Int Soc Sports Nutr       Date:  2017-01-05       Impact factor: 5.150

6.  A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation.

Authors:  Shaun M Cote; Justin Jackson; Michelle Pirruccello-Straub; Gregory J Carven; Stefan Wawersik
Journal:  SLAS Discov       Date:  2019-07-26       Impact factor: 3.341

7.  Effects of elastic band resistance training and nutritional supplementation on muscle quality and circulating muscle growth and degradation factors of institutionalized elderly women: the Vienna Active Ageing Study (VAAS).

Authors:  Marlene Hofmann; Barbara Schober-Halper; Stefan Oesen; Bernhard Franzke; Harald Tschan; Norbert Bachl; Eva-Maria Strasser; Michael Quittan; Karl-Heinz Wagner; Barbara Wessner
Journal:  Eur J Appl Physiol       Date:  2016-03-01       Impact factor: 3.078

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.